ArticleNature medicine2025
Microbial signals in primary and metastatic brain tumors.
Abstract readMulticenter Study
In one paragraph
Article in Nature medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- A Two-Sample Mendelian Randomisation Analysis of the Oral Microbiome and Oral/Oropharyngeal/Tongue Cancers.Oral health & preventive dentistry · 2026Article
- Innovative technologies and future perspectives in tumor microbiomics.Science China. Life sciences · 2026Review
- Microbiota-Neuroinflammation Crosstalk in Primary Brain Tumors: Focus on Glioblastoma.Brain and behavior · 2026Review
- Modeling cancer with bacteria-integrated tumor microenvironments using biomaterials: Emerging concepts and opportunities.Materials today. Bio · 2026Review
- Article
- Diverse origin and nature of tumor-infiltrating lymphocytes: the infection hypothesis.Journal for immunotherapy of cancer · 2026Review
- Multiscale systems modelling of communication networks in brain metastasis.Experimental & molecular medicine · 2026Review
- Spatial Heterogeneity of Intratumoral Microbiota and Its Roles in Tumor-Microbiota Interactions and Therapeutic Implications.Pathogens (Basel, Switzerland) · 2026Review
- Imaging-Based Spatial Transcriptomics: Data Interpretation Methods and Biomedical Applications.Biology · 2026Review
- Intratumoral microbiota in cancer: molecular mechanism and therapeutic strategies.Molecular biomedicine · 2026Review
- Critical assessment of intratumor and low-biomass microbiome using long-read sequencing.bioRxiv : the preprint server for biology · 2026Article
- A new paradigm for treating lung cancer by targeting the intratumoral microbiome.Acta pharmaceutica Sinica. B · 2026Article
- Smart assistive technologies for neurodisorders: A review on AI, IoT, and wearable systems for enhanced patient care.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Review
- The Multi-dimensional Mechanisms and Transformation Prospects of the Intratumoral Microbiota-Arginine Metabolism Axis in Tumor Progression and Immune Regulation.International journal of medical sciences · 2026Review
- Programming the tumor microenvironment through microbiome-driven mechanisms.Frontiers in cellular and infection microbiology · 2026Review
- Bacteria-related signals in brain metastases: evidence boundaries, tumor-microenvironment remodeling, and translational prospects.Frontiers in cell and developmental biology · 2026Review
- Immunosuppressive mechanisms and therapeutic interventions shaping glioblastoma immunity.Nature cancer · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
66 authors.
Golnaz MoradDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. gmorad@mdanderson.org.ORCID http://orcid.org/0000-0002-9460-618X
Ashish V DamaniaPlatform for Innovative Microbiome and Translational Research (PRIME-TR), The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Brenda MelendezPlatform for Innovative Microbiome and Translational Research (PRIME-TR), The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-8789-6791
Bharat B SinghDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Fabiana J VeguillaPlatform for Innovative Microbiome and Translational Research (PRIME-TR), The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Rebecca A SotoPlatform for Innovative Microbiome and Translational Research (PRIME-TR), The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Yasmine M HoballahPlatform for Innovative Microbiome and Translational Research (PRIME-TR), The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Pranoti V SahasrabhojanePlatform for Innovative Microbiome and Translational Research (PRIME-TR), The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Matthew C WongPlatform for Innovative Microbiome and Translational Research (PRIME-TR), The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Mona M AhmedPlatform for Innovative Microbiome and Translational Research (PRIME-TR), The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Rene N RicoDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Kaitlyn N LewisDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Khalida WaniDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Diana D ShamsutdinovaDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Rossana N Lazcano SeguraDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Davis R IngramDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Eric A GoetheDepartment of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Abderrahman DayPlatform for Innovative Microbiome and Translational Research (PRIME-TR), The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ivonne I FloresDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Lauren K McDanielDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Manoj ChelvanambiDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0003-2130-3118
Sarah B JohnsonDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Florentia DimitriouDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Pravesh GuptaDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-1643-8950
Shivangi OberaiDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
M Anna ZalAdvanced Microscopy Core Facility, Department of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-1015-3954
Phoebe DossElectron Microscopy Core Facility,The University of Texas Southwestern, Dallas, TX, USA.
Mohamed A JamalDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Eiko HayaseDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Chetna WathooDepartment of Neuro-oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Lisa M NorbergDivision of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Stephanie L JenkinsDepartment of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0009-0004-9194-0205
Sara NassDepartment of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Joy GuminDepartment of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Lihong LongDepartment of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jing YangDepartment of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Gina R BradleyDepartment of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Mahesh Prasad BekalVivian L. Smith Department of Neurosurgery, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA.ORCID http://orcid.org/0000-0002-6329-0477
Antonio G DonoVivian L. Smith Department of Neurosurgery, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA.
Pavel S Pichardo-RojasVivian L. Smith Department of Neurosurgery, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA.
Samuel W AndrewesDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Leomar Y BallesterDivision of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jillian S LoshPlatform for Innovative Microbiome and Translational Research (PRIME-TR), The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0003-4648-6512
Jiyong LiangDepartment of Neuro-oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Longfei HuoDepartment of Neuro-oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Douglas C NielsenDepartment of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Brittany C Parker KerriganDepartment of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Priscilla K BrastianosBroad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0003-4470-8425
Natalie Wall FowlkesDepartment of Veterinary Medicine and Surgery, Division of Basic Science Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-7711-6031
Chia-Chi ChangDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Robert R JenqDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Candelaria Gomez-ManzanoDepartment of Neuro-oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-1259-2133
Jason T HuseDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Michael A DaviesDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-0977-0912
Alexander J LazarDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-6395-4499
Krishna P BhatDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-2020-8509
Nitin TandonVivian L. Smith Department of Neurosurgery, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA.ORCID http://orcid.org/0000-0002-2752-2365
Yoshua EsquenaziVivian L. Smith Department of Neurosurgery, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA.
Christine B PetersonDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0003-3316-0468
Vinay K PuduvalliDepartment of Neuro-oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Frederick F LangDepartment of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0003-3747-873X
Christopher D JohnstonDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Susan BullmanDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-7713-0810
Nadim J AjamiPlatform for Innovative Microbiome and Translational Research (PRIME-TR), The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-3808-8576
Sherise D FergusonDepartment of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jennifer A WargoDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. jwargo@mdanderson.org.ORCID http://orcid.org/0000-0003-3438-7576
Funding
TRANSLATIONAL AND ANALYTICAL CHEMISTRY COREP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI PETER W PISTERS · 1985 to 2026
$279.3MTropism Enhanced Oncolytic Adenovirus for the Treatment of Brain TumorsP50CA127001 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Juan Fueyo · 2008 to 2026
$41.2MThe University of Texas MD Anderson Cancer Center SPORE in MelanomaP50CA221703 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI WARGO, JENNIFER A. · 2019 to 2023
$10.3MIdentification of genomic drivers of brain metastases in lung adenocarcinomaR01CA227156 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI BRASTIANOS, PRISCILLA KALIOPI, CARTER, SCOTT · 2018 to 2022
$3.5MNCI Diversity Supplement: Glioma therapy with oncolytic adenoviruses and immunometabolic adjuvantsR01CA256006 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI FUEYO, JUAN, GOMEZ-MANZANO, CANDELARIA · 2021 to 2025
$2.0MSuper-Resolution OMX MicroscropeS10RR029552 · NCRR · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ZAL, TOMASZ · 2011 to 2011
$1.0MElucidating the Role of the Gut and Tumor Microbiome in Malignant GliomaR21NS130323 · NINDS · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI FERGUSON, SHERISE DESIREE, WARGO, JENNIFER A. · 2023 to 2024
$446kExamining the Role of Nono Pathway on the Innate Immunity Against Oncolytic AdenovirusesR21CA283514 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Juan Fueyo, Candelaria Gomez-Manzano · 2025 to 2026
$420kTEM for UT Southwestern Electron Microscopy Core FacilityS10OD021685 · OD · UT SOUTHWESTERN MEDICAL CENTER · PI LUBY-PHELPS, KATHERINE J · 2017 to 2017
$398kElucidating the role of gut, blood, and tumor microbiota in brain metastasisF32CA260769 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MORAD, GOLNAZ · 2021 to 2023
$205kNCI NIH HHS F32 CA260769NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA127001NCI NIH HHS P50 CA221703NCI NIH HHS R01 CA227156NCI NIH HHS R01 CA256006NCI NIH HHS R21 CA283514NCRR NIH HHS S10 RR029552NIH HHS S10 OD021685NINDS NIH HHS R21 NS130323U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) 1R01 CA227156-01
Abstract
Gliomas and brain metastases are associated with poor prognosis, necessitating a deeper understanding of brain tumor biology and the development of effective therapeutic strategies. Although our group and others have demonstrated microbial presence in various tumors, recent controversies regarding cancer-type-specific intratumoral microbiota emphasize the importance of rigorous, orthogonal validation. This prospective, multi-institutional study included a total of 243 samples from 221 patients, comprising 168 glioma and brain metastases samples and 75 non-cancerous or tumor-adjacent tissues. Using stringent fluorescence in situ hybridization, immunohistochemistry and high-resolution spatial imaging, we detected intracellular bacterial 16S rRNA and lipopolysaccharides in both glioma and brain metastases samples, localized to tumor, immune and stromal cells. Custom 16S and metagenomic sequencing workflows identified taxa associated with intratumoral bacterial signals in the tumor microenvironment; however, standard culture methods did not yield readily cultivable microbiota. Spatial analyses revealed significant correlations between bacterial 16S signals and antimicrobial and immunometabolic signatures at regional, neighborhood and cellular levels. Furthermore, intratumoral 16S bacterial signals showed sequence overlap with matched oral and gut microbiota, suggesting a possible connection with distant communities. Together, these findings introduce microbial elements as a component of the brain tumor microenvironment and lay the foundation for future mechanistic and translational studies.
Indexed as
Brain NeoplasmsGliomaMicrobiotaAdultAgedBacteriaFemaleHumansIn Situ Hybridization, FluorescenceMaleMiddle AgedProspective StudiesRNA, Ribosomal, 16STumor MicroenvironmentRNA, Ribosomal, 16S
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.